Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Non-Muscle Invasive Bladder Neoplasms 2Head and Neck Neoplasms 2Voice Disorders 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomatitis 1Squamous Cell Carcinoma of Head and Neck 1Papilloma 1Ototoxicity 1Laryngeal Neoplasms 1Hearing Loss 1Goiter 1Esophageal Neoplasms 1Deglutition Disorders 1Cystitis, Interstitial 1Arthralgia 1

Interventions

sodium thiosulfate 4Cisplatin 3Acetylcysteine 2tempol 1ebselen 1Vorinostat 1Thioctic Acid 1Sodium Chloride 1Restraint, Physical 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Pantoprazole 1Methotrexate 1Hydroxymethylglutaryl-CoA Reductase Inhibitors 1Hyaluronic Acid 1Hearing Tests 1Dexamethasone 1Chemotherapy, Adjuvant 1Audiometry 1Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Ototoxicity × Hyaluronic Acid × Clear all
NCT04262336 2023-07-06

Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment

Decibel Therapeutics

Phase 1 Completed
22 enrolled

Ototoxicity, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡